Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.

Inshaw J, Leen C, Fisher M, Gilson R, Hawkins D, Collins S, Fox J, McLean K, Fidler S, Phillips A, Lattimore S, Babiker A, Porter K; UK HIV Seroconverters Cohort.

PLoS One. 2015 Jul 30;10(7):e0132772. doi: 10.1371/journal.pone.0132772. eCollection 2015.

2.

Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.

Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA, Hadigan C.

AIDS Res Hum Retroviruses. 2015 Oct;31(10):961-6. doi: 10.1089/AID.2015.0093. Epub 2015 Aug 24.

PMID:
26214341
3.

Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection.

Truong WR, Schafer JJ, Short WR.

P T. 2015 Jan;40(1):44-55.

4.

Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.

Wu JQ, Saksena MM, Soriano V, Vispo E, Saksena NK.

Virol J. 2015 Jan 27;12:4. doi: 10.1186/s12985-014-0236-6.

5.

The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection.

Kramer JR, Kowalkowski MA, Duan Z, Chiao EY.

J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):456-62. doi: 10.1097/QAI.0000000000000494.

PMID:
25559606
6.

Characteristics of HCV co-infection among HIV infected individuals from an area with high risk of blood-borne infections in central China.

Zhang T, Tully DC, Zhou S, He N.

PLoS One. 2014 Apr 7;9(4):e94219. doi: 10.1371/journal.pone.0094219. eCollection 2014.

7.

Hepatitis C Virus and HIV Type 1 Co-Infection.

Gupta P.

Infect Dis Rep. 2013 Jun 6;5(Suppl 1):e7. doi: 10.4081/idr.2013.s1.e7. eCollection 2013 Jun 6. Review.

8.

The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic.

Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH.

AIDS Patient Care STDS. 2014 Jan;28(1):4-9. doi: 10.1089/apc.2013.0130.

9.

Design and Development of a Multiplex Real-Time PCR Assay for Detection of HIV-1 and HCV Using Molecular Beacons.

Paryan M, Mohammadi-Yeganeh S, Mirab Samiee S, Rezvan H.

Indian J Microbiol. 2012 Sep;52(3):456-63. doi: 10.1007/s12088-012-0271-1. Epub 2012 May 11.

10.

In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use.

Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ.

Am J Clin Nutr. 2013 Aug;98(2):423-9. doi: 10.3945/ajcn.112.048785. Epub 2013 Jun 5.

11.

Design and development of an in-house multiplex RT-PCR assay for simultaneous detection of HIV-1 and HCV in plasma samples.

Paryan M, Forouzandeh MM, Kia V, Mohammadi-Yeganeh S, Abbasali RA, Mirab SS.

Iran J Microbiol. 2012 Mar;4(1):8-14.

12.

HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.

Taylor LE, Swan T, Mayer KH.

Clin Infect Dis. 2012 Jul;55 Suppl 1:S33-42. doi: 10.1093/cid/cis367. Review.

13.

Hepatitis C virus in Arab world: a state of concern.

Daw MA, Dau AA.

ScientificWorldJournal. 2012;2012:719494. doi: 10.1100/2012/719494. Epub 2012 May 2. Review.

14.

Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.

Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE; Actg A5178 Study Team.

HIV Clin Trials. 2012 Mar-Apr;13(2):70-82. doi: 10.1310/hct1302-70.

15.

IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.

Dayyeh BK, Gupta N, Sherman KE, de Bakker PI, Chung RT; Aids Clinical Trials Group A5178 Study Team.

PLoS One. 2011;6(10):e25753. doi: 10.1371/journal.pone.0025753. Epub 2011 Oct 7.

16.

The impact of human T-cell lymphotropic virus I infection on clinical and immunologic outcomes in patients coinfected with HIV and hepatitis C virus.

Bahia F, Novais V, Evans J, Le Marchand C, Netto E, Page K, Brites C.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S202-7. doi: 10.1097/QAI.0b013e31821e9a1e.

17.

Risk Factors and Seroprevalence of Hepatitis C among Patients Hospitalized at Mulago Hospital, Uganda.

O'Reilly JI, Ocama P, Opio CK, Alfred A, Paintsil E, Seremba E, Sofair AN.

J Trop Med. 2011;2011:598341. doi: 10.1155/2011/598341. Epub 2011 Aug 9.

18.

Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Osilla KC, Wagner G, Garnett J, Ghosh-Dastidar B, Witt M, Bhatti L, Goetz MB.

AIDS Patient Care STDS. 2011 Sep;25(9):533-8. doi: 10.1089/apc.2011.0048. Epub 2011 Aug 8.

19.

Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone.

Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA; Veterans Aging Cohort Study Team.

Alcohol Clin Exp Res. 2012 Feb;36(2):318-24. doi: 10.1111/j.1530-0277.2011.01601.x. Epub 2011 Jul 28.

20.

Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients.

Heil EL, Townsend ML, Shipp K, Clarke A, Johnson MD.

AIDS Res Treat. 2010;2010:856542. doi: 10.1155/2010/856542. Epub 2010 Sep 26.

PMID:
21490905
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk